EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Role of Bovine Kappa-Casein Glycomacropeptide in Modulating the Microbiome and Inflammatory Responses of Irritable Bowel Syndrome

Yunyao Qu, Si Hong Park, David C Dallas iD

Nutrients · 2023

DOI: 10.3390/nu15183991 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Nutrients, 2023. Verfasst von Yunyao Qu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Food Science & Technology, Oregon State University, Corvallis, OR 97331, USA. Hauptthemen laut MEDLINE: Irritable Bowel Syndrome, Caseins, Gastrointestinal Microbiome, Peptide Fragments. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 164 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BUILD Dairy, Agropur, Inc, Agropur, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Irritable bowel syndrome (IBS) is a common gastrointestinal disorder marked by chronic abdominal pain, bloating, and irregular bowel habits. Effective treatments are still actively sought. Kappa-casein glycomacropeptide (GMP), a milk-derived peptide, holds promise because it can modulate the gut microbiome, immune responses, gut motility, and barrier functions, as well as binding toxins. These properties align with the recognized pathophysiological aspects of IBS, including gut microbiota imbalances, immune system dysregulation, and altered gut barrier functions. This review delves into GMP’s role in regulating the gut microbiome, accentuating its influence on bacterial populations and its potential to promote beneficial bacteria while inhibiting pathogenic varieties. It further investigates the gut microbial shifts observed in IBS patients and contemplates GMP’s potential for restoring microbial equilibrium and overall gut health. The anti-inflammatory attributes of GMP, especially its impact on vital inflammatory markers and capacity to temper the low-grade inflammation present in IBS are also discussed. In addition, this review delves into current research on GMP’s effects on gut motility and barrier integrity and examines the changes in gut motility and barrier function observed in IBS sufferers. The overarching goal is to assess the potential clinical utility of GMP in IBS management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Irritable Bowel SyndromeCaseinsGastrointestinal MicrobiomePeptide FragmentsAnti-Inflammatory AgentsHumansAnimalsCattleInflammationGastrointestinal MotilityGlycopeptides

Stichwörter der Autor:innen

gut barrier functiongut microbiomegut motilityinflammationirritable bowel syndrome (IBS)kappa-casein glycomacropeptide (GMP)therapeutic benefits

Substanzen

Caseinskappa-casein glycomacropeptidePeptide FragmentscaseinomacropeptideAnti-Inflammatory AgentsGlycopeptides

Autor:innen und Institutionen

  • Department of Food Science & Technology, Oregon State University, Corvallis, OR 97331, USA.
  • Nutrition Program, College of Health, Oregon State University, Corvallis, OR 97331, USA.

ORCID-Profile: David C Dallas

Förderung

  • BUILD Dairy
  • Agropur, Inc
  • Agropur, Inc.

Zitieren

APA

Qu, Y., Park, S. H., & Dallas, D. C. (2023). The Role of Bovine Kappa-Casein Glycomacropeptide in Modulating the Microbiome and Inflammatory Responses of Irritable Bowel Syndrome. Nutrients. https://doi.org/10.3390/nu15183991

Vancouver

Qu Y, Park SH, Dallas DC. The Role of Bovine Kappa-Casein Glycomacropeptide in Modulating the Microbiome and Inflammatory Responses of Irritable Bowel Syndrome. Nutrients. 2023. doi:10.3390/nu15183991

BibTeX
@article{Qu2023,
  author = {Qu, Yunyao and Park, Si Hong and Dallas, David C},
  title = {The Role of Bovine Kappa-Casein Glycomacropeptide in Modulating the Microbiome and Inflammatory Responses of Irritable Bowel Syndrome},
  journal = {Nutrients},
  year = {2023},
  doi = {10.3390/nu15183991}
}
Kostenlos starten →